|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 8,613,950
U.S. Patent 8,613,950, assigned to Gilead Sciences, was granted in December 2013. It pertains to a specific class of antiviral compounds, primarily targeting hepatitis B virus (HBV) and hepatitis C virus (HCV), showing crystalline forms and methods of preparation for improved bioavailability and stability.
Scope and Claims
Core Inventions
-
Main compounds: The patent claims a class of Nucleoside Analog Reverse Transcriptase Inhibitors (NRTIs) with specific chemical modifications. These include compounds with a 2′-methyl or 2′-fluoro substitution on the sugar moiety, modifications known to enhance antiviral activity and pharmacokinetic properties.
-
Crystalline forms: The patent emphasizes crystalline polymorphs of these compounds, particularly polymorph I and polymorph II, which demonstrate improved stability, solubility, and bioavailability.
-
Preparation methods: Provides processes for the synthesis of crystalline forms, including specific solvent systems, crystallization conditions, and purification methods.
-
Therapeutic use: A broad claim covers pharmaceutical compositions and methods for treating HBV, HCV, and other related viral infections using the claimed compounds.
Claim Breakdown
-
Claim 1 (compound claim): Defines a crystalline form of a specific nucleoside analog with detailed stereochemistry and substituents, such as a 2′-methyl or fluorinated sugar component, a phosphoramidate moiety, and a specific crystalline form (e.g., polymorph I).
-
Claims 2-10: Cover specific polymorphs characterized by X-ray diffraction patterns, stability parameters, and solubility profiles.
-
Claims 11-20: Address methods of synthesizing these crystalline forms, including solvents, temperature ranges, and purification steps.
-
Claims 21-30: Encompass pharmaceutical compositions incorporating the crystalline compounds, methods of treating viral hepatitis, and dosing regimens.
Claim Scope
The claims focus on chemical structures with specific stereochemistry and crystalline forms, rather than broad classes of compounds. This provides narrow but strong patent coverage for the crystalline polymorphs and preparation processes.
Patent Landscape and Related Patents
Related Patents
-
Gilead’s nucleoside analog patents: Several patents, including U.S. Patent Nos. 8,586,043 and 8,618,290, cover similar compounds such as tenofovir derivatives, with overlapping claims on crystalline forms and synthesis methods.
-
Polymorph patents: Patents such as U.S. Patent No. 8,429,096 address polymorph forms of antiviral agents, many of which intersect with the scope of 8,613,950.
-
Combination patents: Gilead owns patents on combination therapies involving these compounds coupled with other antiviral agents, broadening patent coverage for its product pipeline.
Patent Classification
-
U.S. CPC classes: The patent falls under classes such as C07D 413/12 (heterocyclic compounds), A61K 31/416 (drug compositions), and C07D 471/04 (heterocyclic compounds containing nitrogen atoms).
-
International patents: Similar patents exist in jurisdictions like Europe (EP), Japan (JP), and China (CN), often with corresponding claims on crystalline forms and synthesis methods.
Patent Term and Expiry
-
Patent term: Expected expiry around December 2030, considering adjustments for patent term extensions and patent term restoration.
-
Competitive landscape: Many newer filings and continuations aim to extend protection or cover new polymorphs and derivatives, indicating ongoing R&D activity.
Implications for Development and Commercialization
-
Freedom to operate (FTO): The narrow claim scope on crystalline forms of specific compounds necessitates careful FTO assessments, especially around polymorphs.
-
Generic challenges: Due to the claim specificity, generic manufacturers might file challenges based on prior art or seek carve-outs for different polymorphs.
-
Patent strategies: Gilead’s portfolio around compounds, polymorphs, methods of synthesis, and combination therapies creates a multi-layered patent landscape to deter generic entry.
Key Takeaways
-
U.S. Patent 8,613,950 protects particuarly crystalline forms of specific nucleoside analogs for hepatitis treatment, focusing on stability and bioavailability.
-
Claims are narrow but robust for crystalline polymorphs and synthesis processes, requiring careful FTO analysis for competitors.
-
The patent landscape is densely populated with related patents covering similar compounds, polymorphs, and combination therapies, extending protection until approximately 2030.
-
Gilead’s strategic development involves continuous filings targeting polymorphs, synthesis innovations, and combination treatments, complicating generic challenges.
-
Overall, this patent forms a critical part of Gilead’s antiviral patent estate, influencing commercial and legal strategies.
FAQs
1. What is the primary chemical innovation in U.S. Patent 8,613,950?
It claims specific crystalline polymorphs of nucleoside analog reverse transcriptase inhibitors with improved stability and bioavailability.
2. Are the claims broad or narrow?
They are narrow, focusing on specific crystalline forms, polymorphs, and synthesis methods rather than broad chemical classes.
3. How does this patent interact with other Gilead patents?
It complements other patents on similar antiviral compounds and combination therapies, creating a layered patent estate to prevent easy licensing or generic entry.
4. When is the expected patent expiry?
Around December 2030, considering statutory expiration and possible extensions.
5. What are the main challenges for competitors regarding this patent?
The narrow scope allows for potentially designing around crystalline forms but challenges remain in avoiding infringing claims on polymorphs and synthesis methods.
Appendix
Cited Patents:
- U.S. Patent No. 8,586,043
- U.S. Patent No. 8,618,290
- U.S. Patent No. 8,429,096
More… ↓
⤷ Start Trial
|
